DARNITSA GROUP
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

DARNITSA GROUP Trademark

Serial Number: 79276074 • Registration: 6235826

DARNITSA GROUP is a trademark filed by PRIVATE JOINT STOCK COMPANY “PHARMACEUTICAL FIRM "DARNITSA" on October 7, 2019. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

PRIVATE JOINT STOCK COMPANY “PHARMACEUTICAL FIRM "DARNITSA" (2 trademarks)

13 Boryspilska Street

Entity Type: 99

Zahorii Hlib Volodymyrovych (3 trademarks)

13 Boryspilska Street

Entity Type: 01

Trademark Details

Filing Date

October 7, 2019

Registration Date

January 5, 2021

Published for Opposition

October 20, 2020

Goods & Services

Antiseptics; vaccines; veterinary preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vitamin preparations; disinfectants; diagnostic preparations for veterinary purposes; diagnostic preparations for medical purposes; dietetic beverages adapted for medical purposes; Dietetic foods and beverages adapted for medical use; dietetic foods adapted for medical purposes; plant extracts for pharmaceutical purposes; herbal extracts for medical purposes; Capsules sold empty for pharmaceuticals; medicinal preparations for human purposes for medicines for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Drugs for medical purposes for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Medicinal drinks; medicinal oils; medicated toiletry preparations; medicated shampoos; ointments for pharmaceutical purposes for ointments for pharmaceutical purposes, namely, medicated ointments for treating dermatological conditions and antibiotic ointments; teeth filling material; medicinal alcohol; food supplements; medical dressings; nutritional supplements; Pre-filled syringes containing pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Air purifying preparations; food for babies; protein dietary supplements; Tissues impregnated with pharmaceutical lotions for treating dermatological conditions; Alcohol for pharmaceutical purposes; stem cells for medical purposes; transplants, namely, surgical implants comprising living tissue used in transplant operations; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; ferments for pharmaceutical purposes; phytotherapy preparations for medical purposes; chemico-pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Chemical preparations for medical purposes for the diagnosis of pregnancy; Chemical preparations for pharmaceutical purposes for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Chemical reagents for medical or veterinary purposes; surgical glues; surgical dressings; candy, medicated; candy for medical purposes; sanitary preparations for medical purposes; plasters for medical purposes

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jan 4, 2025 NREP
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Aug 3, 2023 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 3, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 3, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 3, 2023 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
May 30, 2021 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Apr 9, 2021 XXSS
GENERIC MADRID TRANSACTION CREATED
Apr 9, 2021 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 5, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Jan 5, 2021 R.PR
NEW REPRESENTATIVE AT IB RECEIVED
Dec 18, 2020 NREP
NOTIFICATION PROCESSED BY IB
Dec 6, 2020 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 13, 2020 OPNS
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 20, 2020 NPUB
PUBLISHED FOR OPPOSITION
Oct 20, 2020 PUBO
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Sep 30, 2020 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 30, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 17, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 3, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 3, 2020 CRFA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 3, 2020 TEME
ASSIGNED TO LIE
Sep 3, 2020 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Aug 13, 2020 PARI
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 12, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 12, 2020 TROA
REFUSAL PROCESSED BY IB
Feb 28, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 12, 2020 RFCS
REFUSAL PROCESSED BY MPU
Feb 12, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 18, 2020 RFCR
NON-FINAL ACTION WRITTEN
Jan 17, 2020 CNRT
APPLICATION FILING RECEIPT MAILED
Jan 14, 2020 MAFR
ASSIGNED TO EXAMINER
Jan 10, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 10, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 9, 2020 REPR